Zhao-Ru Dong

Dr. Zhao-Ru Dong


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
XDXiao-Feng Dong
Xiao-Feng Dong
TLTian-Qi Liu
Tian-Qi Liu
XZXu-Ting Zhi
Xu-Ting Zhi
JZJie Zou
Jie Zou
JZJing-Tao Zhong
Jing-Tao Zhong
ZDZhao-Ru Dong
Zhao-Ru Dong
Purpose: Hypoxia-inducible factor-2α (HIF2α) is regarded as a preferential target for individualized hepatocellular carcinoma (HCC) treatment and sorafenib resistance. Our study aimed to identify the regulatory mechanisms of HIF2α activity under hypoxic conditions. We sought to determine whether the COX-2/PGE2 axis is involved in the regulatory mechanisms of HIF2α activity and of sorafenib resistance in hypoxic HCC cells. Experimental Design: The cell viability, migration, and invasion abilities were measured to analyze the effects of HIF2α on hypoxic HCC cells. Both in vitro and in vivo HCC models were used to determine whether the COX-2/PGE2 axis is a driver of HIF2α level and activity, which then reduces the sensitivity of sorafenib treatment in hypoxic HCC cells. Results: Under hypoxic conditions, the COX-2/PGE2 axis effectively stabilized HIF2α and increased its level and activity via decreasing von Hippel-Lindau protein (p-VHL) level, and also enhanced HIF2α activity by promoting HIF2α nuclear translocation via MAPK pathway. The activation of HIF2α then led to the enhanced activation of VEGF, cyclin D1, and TGFα/EGFR pathway to mediate HCC development and reduce the sensitivity of sorafenib. More importantly, COX-2–specific inhibitors synergistically enhanced the antitumor activity of sorafenib treatment. Conclusions: Our data obtained demonstrate that the COX/PGE2 axis acts as a regulator of HIF2α expression and activity to promote HCC development and reduce sorafenib sensitivity by constitutively activating the TGFα/EGFR pathway. This study highlights the potential of COX-2–specific inhibitors for HCC treatment and particularly for enhancing the response to sorafenib treatment. Clin Cancer Res; 24(13); 3204–16. ©2018 AACR.

6 July 2023 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YYYu-Chuan Yan
Yu-Chuan Yan
GMGuang-Xiao Meng
Guang-Xiao Meng
CYChun-Cheng Yang
Chun-Cheng Yang
YYYa-Fei Yang
Ya-Fei Yang
STSi-Yu Tan
Si-Yu Tan
TLTao Li
Tao Li
As an important hydrolytic enzyme that yields 2-AG and free fatty acids, diacylglycerol lipase alpha (DAGLA) is involved in exacerbating malignant phenotypes and cancer progression, but the role of the DAGLA/2-AG axis in HCC progression remains unclear. Here, we found that the upregulation of components of the DAGLA/2-AG axis in HCC samples is correlated with tumour stage and patient prognosis. In vitro and in vivo experiments demonstrated that the DAGLA/2-AG axis promoted HCC progression by regulating cell proliferation, invasion and metastasis. Mechanistically, the DAGLA/2AG axis significantly inhibited LATS1 and YAP phosphorylation, promoted YAP nuclear translocation and activity, and ultimately led to TEAD2 upregulation and increased PHLDA2 expression, which could be enhanced by DAGLA/2AG-induced activation of the PI3K/AKT pathway. More importantly, DAGLA induced resistance to lenvatinib therapy during HCC treatment. Our study demonstrates that inhibiting the DAGLA/2-AG axis could be a novel therapeutic strategy to inhibit HCC progression and enhance the therapeutic effects of TKIs, which warrant further clinical studies.

29 June 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ZDZi-Niu Ding
Zi-Niu Ding
GMGuang-Xiao Meng
Guang-Xiao Meng
JXJun-Shuai Xue
Jun-Shuai Xue
LYLun-Jie Yan
Lun-Jie Yan
HLHui Liu
Hui Liu
TLTao Li
Tao Li

7 March 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
LYLun-Jie Yan
Lun-Jie Yan
LYLong-Shan Yang
Long-Shan Yang
YYYu-Chuan Yan
Yu-Chuan Yan
STSi-Yu Tan
Si-Yu Tan
ZDZi-Niu Ding
Zi-Niu Ding
TLTao Li
Tao Li

1 January 2017 in Journal of Cancer
Verified
Journal Article
Open access
ZDZhao-Ru Dong
Zhao-Ru Dong
JZJie Zou
Jie Zou
DSDong Sun
Dong Sun
GSGuo-Ming Shi
Guo-Ming Shi
AKAi-Wu Ke
Ai-Wu Ke
JFJia Fan
Jia Fan
Surgical resection remains the initial treatment of choice for the majority of early stage hepatocellular carcinoma (HCC) patients. Although the factors that influence the prognosis of postoperative HCC patients have been well elucidated, there are a limited number of simple, objective, and distinct methods for estimating survival for postoperative patients with solitary HCC within the Milan criteria and Child-Pugh (C-P) A cirrhosis. The Albumin-Bilirubin (ALBI) score is a new evidence-based approach to assess liver function. The ALBI score eliminates subjective variables, such as ascites and encephalopathy which are the requirements for the conventional C-P grading system. This study enrolled 654 patients to determine whether the ALBI score can predict the outcomes of postoperative solitary HCC patients within the Milan criteria and C-P A cirrhosis. Our results showed the ALBI score significantly influenced the overall survival and cumulative recurrence rates. Furthermore, the ALBI score was significantly related to the degree of liver cirrhosis and serum γ-glutamyl transpeptidase (GGT) concentration in solitary HCC cases within the Milan criteria and C-P A cirrhosis. Additionally, the combination of the ALBI score and serum GGT concentration contributed to the prognosis prediction in this cohort. In conclusion, we externally validated the ALBI grade as a novel biomarker to predict prognosis for solitary HCC within the Milan Criteria and C-P A cirrhosis.

18 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
DBDousheng Bai
Dousheng Bai
CWChao Wu
Chao Wu
LYLiu-Xiao Yang
Liu-Xiao Yang
CZChi Zhang
Chi Zhang
PZPengfei Zhang
Pengfei Zhang
GSGuo-Ming Shi
Guo-Ming Shi
UBAP2 negatively regulates the invasion of hepatocellular carcinoma cell by ubiquitinating and degradating Annexin A2